Markedly Enhanced Susceptibility to Experimental Autoimmune Myasthenia Gravis in the Absence of Decay-Accelerating Factor Protection

Journal of Clinical Investigation - United States
doi 10.1172/jci0216086
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Immunosuppression of Experimental Autoimmune Myasthenia Gravis by Mycophenolate Mofetil

Journal of Neuroimmunology
AllergyImmunologyNeurology
2008English

A New Method to Induce Myasthenia Gravis Models and the Protective Effect of Soluble Decay Accelerating Factors

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Absence of IL-4 Facilitates the Development of Chronic Autoimmune Myasthenia Gravis in C57bl/6 Mice

Journal of Immunology
AllergyImmunology
2003English

Ephedrine Treatment for Autoimmune Myasthenia Gravis

Neuromuscular Disorders
Child HealthNeurologyPediatricsPerinatologyGenetics
2017English

Complicating Autoimmune Diseases in Myasthenia Gravis: A Review

Autoimmunity
AllergyImmunology
2015English

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis

Journal of Neuromuscular Diseases
Neurology
2018English

Absence of Cellular Hypersensitivity to Muscle and Thymic Antigens in Myasthenia Gravis.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1975English

Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats

Frontiers in Physiology
Physiology
2016English

Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity

The Lancet Neurology
Neurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy